Literature DB >> 1691221

Targeted cytotoxic cells in human peripheral blood lymphocytes.

M A Garrido1, P Perez, J A Titus, M J Valdayo, D F Winkler, S A Barbieri, J R Wunderlich, D M Segal.   

Abstract

We have isolated subsets of cells from human PBL and have investigated their abilities to mediate lysis targeted by bispecific antibodies. Targeted cytotoxic cells were divided into two distinct types based on buoyant density. The low buoyant density fraction contained all of the targetable cytotoxic activity in unstimulated PBL, including both T and K cells targeted with anti-CD3 and anti-Fc gamma RIII (CD16) containing bispecific antibodies, respectively. Both types of targetable cytotoxic cells required IL-2 for maintenance of cytotoxic activity, expressed the CD56 (NKH1) marker, and mediated MHC-unrestricted lysis. The targetable T cells in low density PBL were exclusively CD8+ and represented only about 2% of the total PBL. The high buoyant density lymphocytes, depleted of NK cells, had no targetable activity, but were able to generate over several days, targetable T cell activity in the presence of a TCR cross-linking signal plus IL-2. Unlike the low-density cells, the activated high buoyant density effector T cells did not express CD56, consisted of both CD4+ and CD8+ cells, and did not mediate MHC-unrestricted lysis. These cells proliferated more rapidly and generated more total lytic activity than the low-density fraction. Our studies show that targetable cytotoxic activity in human PBL is mediated by several subsets of cells with different activation requirements. Presumably all of these activities could be directed against unwanted cells in clinical or preclinical studies involving targeted cytotoxic cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691221

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.

Authors:  M Azuma; M Cayabyab; D Buck; J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

2.  Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins.

Authors:  T J Wickham; E Tzeng; L L Shears; P W Roelvink; Y Li; G M Lee; D E Brough; A Lizonova; I Kovesdi
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Targeted adenovirus-mediated gene delivery to T cells via CD3.

Authors:  T J Wickham; G M Lee; J A Titus; G Sconocchia; T Bakács; I Kovesdi; D M Segal
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Requirement of monocytes and T-helper cells during development of tumor cell cytotoxicity in targeted T cells.

Authors:  K A Smans; M F Hoylaerts; M E De Broe
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

5.  The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes.

Authors:  A G Hadley; B Zupanska; B M Kumpel; K A Leader
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

6.  Promotion of natural killer cell growth in vitro by bispecific (anti-CD3 x anti-CD16) antibodies.

Authors:  A M Malygin; K Somersalo; T Timonen
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

7.  Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells.

Authors:  B J Kroesen; A ter Haar; H Spakman; P Willemse; D T Sleijfer; E G de Vries; N H Mulder; H H Berendsen; P C Limburg; T H The
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

8.  A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.

Authors:  M Mack; G Riethmüller; P Kufer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

9.  Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.

Authors:  I A Haagen; W B de Lau; B J Bast; A J Geerars; M R Clark; B C de Gast
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

Review 10.  Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity.

Authors:  Carin I M Dahlberg; Dhifaf Sarhan; Michael Chrobok; Adil D Duru; Evren Alici
Journal:  Front Immunol       Date:  2015-11-30       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.